Navigation Links
NxStage Reports First Quarter 2013 Financial Results
Date:5/2/2013

LAWRENCE, Mass., May 2, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported first quarter financial results with revenue at the upper end of its guidance range.

(Logo:  http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

Revenue for the first quarter of 2013 increased 8% to $61.6 million, compared with revenue of $57.0 million for the first quarter of 2012.  The higher revenues were driven by increased adoption of the NxStage System One™.

Home revenue for the first quarter of 2013 increased 6% to $31.5 million compared with revenue of $29.6 million for the first quarter of 2012.  These results, which reflect the Company's transition to a direct sales operation from a distribution relationship in the United Kingdom, were in-line with the Company's guidance.

Critical Care revenue increased to $10.7 million for the first quarter of 2013 compared with revenue of $9.8 million for the first quarter of 2012.  In-center revenue increased to $18.7 million for the first quarter of 2013 compared with revenue of $17.6 million for the first quarter of 2012. 

NxStage reported a net loss of $5.0 million or $(0.08) per share for the first quarter of 2013 compared with a net loss of $5.1 million or $(0.09) per share for the first quarter of 2012.  The Company's first quarter net loss reflects increased investments in new products and market development efforts to accelerate future revenue growth.

"Our first quarter performance represents a good start to the year," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage.  "In addition to meeting our near-term financial objectives, we're on track with strong and systematic execution against initiatives that are focused on accelerating growth over the long term.  Our recent regulatory successes which include approval for a number of significant product innovations, including CE mark for nocturnal home dialysis and both CE mark and FDA clearance for our new high flow capabilities with our System One, reinforce our confidence in our ability to reduce barriers to home adoption and drive demand for our therapy."

Burbank continued, "Based on our outlook and our continuing progress in key areas, we are reaffirming both our guidance for 2013, and our belief that we are creating significant catalysts for adoption of NxStage therapies in 2014 and beyond."

Guidance:

For the second quarter of 2013, the Company is forecasting revenues to be between $64.0 million and $65.5 million, a net loss in the range of $4.0 million to $5.0 million, or $(0.07) to $(0.08) per share.  The Company reaffirmed its full year guidance for 2013.

Conference Call:NxStage will also host a conference call today, Thursday, May 2, 2013 at 9:00 a.m. Eastern Time to discuss its first quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international).  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com.

A replay of the conference call will be available 2 hours after the completion of the call through May 9, 2013.  To access the replay dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 34519800.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com.

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:
Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com

Non-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below. 

 NxStage Medical, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except per share data)
(unaudited)Three Months Ended
March 31,  20132012Revenues

$
,644$
56,951Cost of revenues

37,64435,639Gross profit

24,00021,312Operating expenses:Selling and marketing

10,6969,920Research and development

5,1083,897Distribution

4,9084,532General and administrative

7,8246,622Total operating expenses

28,53624,971Loss from operations

(4,536)(3,659)Other expense:Interest expense

(150)(1,193)Other expense, net

(176)(52)(326)(1,245)Net loss before income taxes

(4,862)(4,904)Provision for income taxes

132240Net loss

$   (4,994)$
(5,144)Net loss per share, basic and diluted

$
(0.08)$
(0.09)Weighted-average shares outstanding, basic and diluted

59,38155,773Other comprehensive gain

145173Total comprehensive loss

$   (4,849)$
(4,971) NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)March 31,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents

$

99,803$

106,439Accounts receivable, net

22,05818,990Inventory

36,96633,504Prepaid expenses and other current assets

4,8252,534Total current assets

163,652161,467Property and equipment, net

37,31736,320Field equipment, net

10,29710,101Deferred cost of revenues

36,13538,028Intangible assets, net

19,12019,819Goodwill

42,42142,421Other assets

3,2613,793Total assets

$

312,203$

311,949LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$

20,593$

16,645Accrued expenses

19,56120,400Other current liabilities

2,1652,187Total current liabilities

42,31939,232Deferred revenues

57,19159,262Other long-term liabilities

15,92015,864Total liabilities

115,430114,358Commitments and contingenciesStockholders' equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized;  no
shares issued and outstanding as of March 31, 2013 and December 31, 2012

——Common stock: par value $0.001, 100,000,000 shares authorized; 60,279,658 and 
59,850,117 shares issued as of March 31, 2013 and December 31, 2012, respectively

6059Additional paid-in capital

555,850551,594Accumulated deficit

(349,975)(344,981)Accumulated other comprehensive income

615470Treasury stock, at cost: 561,808 and 541,584 shares as of March 31, 2013 and
December 31, 2012, respectively

(9,777)(9,551)Total stockholders' equity

196,773197,591Total liabilities and stockholders' equity

$

312,203$

311,949  

NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Three Months Ended March 31,

2013 2012Cash flows from operating activities:Net loss$  (4,994)$  (5,144)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization6,0805,720Stock-based compensation2,6463,199Other230794Changes in operating assets and liabilities:Accounts receivable(3,072)(1,779)Inventory(6,350)(4,738)Prepaid expenses and other assets(1,474)(96)Accounts payable4,124(32)Accrued expenses and other liabilities(511)1,916Deferred revenues(1,887)(1,248)Net cash used in operating activities$  (5,208)$  (1,408) NxStage Medical, Inc.
Revenues by Segment
(in thousands)
(unaudited)Three Months Ended
March 31,20132012System One segmentHome$ 31,459$ 29,553Critical Care10,7109,787Total System One segment42,16939,340In-Center segment18,70017,611Other775—Total$ 61,644$ 56,951 NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months Ended March 31,20132012Net loss

$

(5.0)$

(5.1)Less: Depreciation, amortization, interest, and taxes

6.57.2Less: Adjusting items*

(1.2)(0.3)Adjusted EBITDA

$

0.3$

1.8* Adjusting items include stock-based compensation, deferred revenue recognized,
  manufacturing transition costs and other non-cash expenses 


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
2. NxStage Names Robert G. Funari Chairman Of The Board
3. NxStage Completes Move to Direct Sales In UK
4. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
5. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
6. NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
7. NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
8. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
9. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
10. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 Global ... industry including definitions, classifications, applications and industry chain structure. ... market including development history, competitive landscape analysis, and major ... ... spread across 105 pages providing 10 company profiles and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
Breaking Medicine News(10 mins):